The primary purpose of this study was to investigate the effect of a catalyzed continuously regenerating trap (CCRT) system composed of a diesel oxidation catalyst (DOC) and a catalyzed diesel particulate filter (CDPF) on the main gaseous and particulate emissions from an urban diesel bus, as well as the durability performance of the CCRT system. Experiments were conducted based on a heavy chassis dynamometer, and a laboratory activity test as well as X-ray photoelectron spectroscopy (XPS) test were applied to evaluate the changes of the aged CCRT catalyst. Results showed that the CCRT could reduce the CO by 71.5% and the total hydrocarbons (THC) by 88.9%, and meanwhile promote the oxidation of NO. However, the conversion rates for CO and THC dropped to 25.1% and 55.1%, respectively, after the CCRT was used for one year (~60,000 km), and the NO oxidation was also weakened. For particulate emissions, the CCRT could reduce 97.4% of the particle mass (PM) and almost 100% of the particle number (PN). The aging of the CCRT resulted in a reduced PM trapping efficiency but had no observable effect on the PN; however, it increased the proportion of nucleation mode particles. The activity test results indicated that the deterioration of the CCRT was directly relevant to the increase in the light-off temperatures of the catalyst for CO, CH and NO. In addition, the decreased concentrations of the active components Pt and Pt in the catalyst are also important factors in the CCRT deterioration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jes.2019.05.001 | DOI Listing |
Anticancer Res
January 2025
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.
Patients And Methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021.
Future Oncol
December 2024
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Aims: This study aimed at developing a scoring system (EAST score) to predict recurrence after chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC).
Patients & Methods: Treatment-naïve LS-SCLC patients receiving concurrent chemoradiotherapy (CCRT) ( = 234) or sequential chemoradiotherapy ( = 53) were retrospectively reviewed. Using data from CCRT population, clinical and radiological variables associated with disease progression were identified.
Asian Pac J Cancer Prev
December 2024
Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Background: Colorectal cancer is a significant global health concern, with Thailand reporting notable incidence rates. Locally advanced rectal cancer demands effective treatment strategies to reduce the risk of local recurrence post-surgery; however, the predictive factors for local recurrence are uncertain..
View Article and Find Full Text PDFSci Rep
December 2024
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Texture analysis generates image parameters from F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Although some parameters correlate with tumor biology and clinical attributes, their types and implications can be complex. To overcome this limitation, pseudotime analysis was applied to texture parameters to estimate changes in individual sample characteristics, and the prognostic significance of the estimated pseudotime of primary tumors was evaluated.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
This study aimed to find a safe and effective cumulative cisplatin dose (CCD) for concurrent chemoradiotherapy (CCRT) beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients. A total of 765 elderly (≥ 60 years old) NPC patients treated with cisplatin-based CCRT and IMRT-alone from 2007 to 2018 were included in this study. RPA-generated risk stratification was used to identify CCRT beneficiaries.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!